|
Primary sclerosing cholangitis
|
0.310 |
Biomarker
|
disease |
BEFREE |
Of interest with regard to PSC is the finding that BCL2L11-deficient mice develop periductular infiltrates.
|
27630216 |
2017 |
|
Primary sclerosing cholangitis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.
|
21151127 |
2011 |
|
Prostate cancer, familial
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
PROSTATE CANCER, HEREDITARY, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease.
|
28869590 |
2017 |
|
Cholangitis, Sclerosing
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.
|
21151127 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Abbreviations: APC/C: Anaphase-Promoting Complex/Cyclosome; BAD: BCL2-Associated agonist of cell Death; BAK1: BCL2 Antagonist Kinase1; BAX: BCL2-Associated X; BCL2: B-cell Chronic Lymphocytic Leukaemia (CLL)/Lymphoma 2; BH: BCL2 Homology Domain; BID: BH3-Interacting domain Death agonist; BIM: BCL2-Interacting Mediator of cell death; BUB: Budding Uninhibited by Benzimidazoles; CDC: Cell Division Cycle; CDH1: Cadherin-1; CDK1: Cyclin-Dependent Kinase 1; CEP55: Centrosomal Protein (55 KDa): CIN: Chromosomal Instability; CTA: Cancer Testis Antigen; EGR1: Early Growth Response protein 1; ERK: Extracellular Signal-Regulated Kinase; ESCRT: Endosomal Sorting Complexes Required for Transport; GIN: Genomic Instability; MAD2: Mitotic Arrest Deficient 2; MCL1: Myeloid Cell Leukemia sequence 1; MPS1: Monopolar Spindle 1 Kinase; MYT1: MYelin Transcription factor 1; PLK1: Polo Like Kinase 1; PUMA: p53-Upregulated Mediator of Apoptosis; SAC: Spindle Assembly Checkpoint; TAA: Tumor-Associated Antigen.
|
30601084 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
The authors' previous study demonstrated that the B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (BCL2L11) (Bim) deletion polymorphism was associated with poor clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC) with EGFR mutations.
|
28346673 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.
|
26956414 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
The extent of mitochondrial depolarization by a BIM BH3 peptide in vitro was correlated with percentage reduction of CLL in the blood and bone marrow in vivo, whereas the half lethal concentration derived from standard cytotoxicity assays was not.
|
27069256 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Further analyses suggest that Tris-DBA-induced apoptosis involves reduced expression of the anti-apoptotic proteins Bcl-xL, and XIAP with an upregulation of the pro-apoptotic protein BIM in CLL B-cells.
|
27189785 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have indicated that some patients with positive mutations were refractory to EGFR TKIs if they harbored a B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (Bim) deletion polymorphism.
|
24737648 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Furthermore, we observed that higher expression of DUSP5 in relation to DUSP5P1 correlated with the expression of the pro-apoptotic factor B cell leukemia/lymphoma 2-like 11 (BCL2L11) in peripheral blood cells and HL cells.
|
24651368 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Resistance was associated with a partial reactivation of extracellular signal-regulated kinase 1/2 (ERK1/2) signaling, recovery of G1/S cell-cycle events, and suppression of the pro-apoptotic B-cell leukemia/lymphoma 2 (Bcl-2) homology domain 3 (BH3)-only proteins, Bcl-2-interacting mediator of cell death-extra large (Bim-EL) and Bcl-2 modifying factor (Bmf).
|
22858545 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Coculture of CLL cells with HK cells, a model of the CLL microenvironment, promoted CLL cell survival and was associated with MEK1/2 activation and BIM(EL) phosphorylation.
|
22160382 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Instead, BCL2 complexed to BIM is the critical target for ABT-737 in CLL.
|
17200714 |
2007 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
Biomarker
|
disease |
LHGDN |
We have studied the regulation of the proapoptotic BH3-only Bcl-2 interacting mediator of cell death (BIM) in CLL cells.
|
17151701 |
2007 |
|
Breast Carcinoma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Uev1A promotes cell survival under serum starvation stress through the AKT-FOXO1-BIM axis in breast cancer cells, which unveals a potential therapeutic target in the treatment of breast cancers.
|
31827405 |
2019 |
|
Breast Carcinoma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Univariate and multivariate regression analysis showed that Bim was an independent prognostic factor for breast cancer (P< 0.05).
|
28582840 |
2017 |
|
Breast Carcinoma
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
|
Breast Carcinoma
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
BIM deletion polymorphism may be involved in the tumorigenesis of the early-onset breast cancer among East Asians.
|
25909194 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with EGFR-mutated NSCLC with the BIM deletion, pre-treated with EGFR-TKI and chemotherapy, were recruited.
|
31782583 |
2020 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mechanistic study using a cancer pathway specific transcriptomic array revealed a significant overexpression of the pro-apoptotic gene BCL2L11 (Bim) in the miR-29b overexpressed PC3 cells, which was further verified in PC3 cells overexpressing miR-29b.
|
31752117 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After adjusting with clinical factors, different ALK variants and BIM polymorphism might not be independent factors for crizotinib PFS or OS in advanced NSCLC with ALK rearrangement.
|
31608224 |
2019 |